Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
Antibody-dependent cellular phagocytosis in antiviral immune responses
MZ Tay, K Wiehe, J Pollara - Frontiers in immunology, 2019 - frontiersin.org
Antiviral activities of antibodies may either be dependent only on interactions between the
antibody and cognate antigen, as in binding and neutralization of an infectious virion, or …
antibody and cognate antigen, as in binding and neutralization of an infectious virion, or …
[HTML][HTML] Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19
GD Sempowski, KO Saunders, P Acharya, KJ Wiehe… - Cell, 2020 - cell.com
The SARS-CoV-2 pandemic that causes COVID-19 respiratory syndrome has caused global
public health and economic crises, necessitating rapid development of vaccines and …
public health and economic crises, necessitating rapid development of vaccines and …
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …
ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers
Protein–protein interactions are essential to cellular and immune function, and in many
cases, because of the absence of an experimentally determined structure of the complex …
cases, because of the absence of an experimentally determined structure of the complex …
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity
INTRODUCTION Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) have been circulating worldwide since the beginning of the pandemic. Some are termed …
2) have been circulating worldwide since the beginning of the pandemic. Some are termed …
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Summary SARS-CoV-2-neutralizing antibodies (NAbs) protect against COVID-19. A concern
regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we …
regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we …
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …
vaccine demonstrated an estimated efficacy of 31%, which correlated directly with …
[HTML][HTML] Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
…, DC Douek, MA Tomai, CB Fox, R Seder, K Wiehe… - Nature, 2021 - nature.com
Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 …
Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 …
[HTML][HTML] Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody
Antibodies with ontogenies from VH 1-2 or VH 1-46-germline genes dominate the broadly
neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with …
neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with …